Data at Heart Rhythm 2026 highlight key Boston Scientific therapies
: Many analysts, including those from Barclays and Goldman Sachs , see the current price (near its 52-week low of ~$59) as an attractive entry point with predicted upsides ranging from 37% to over 50%. bsx stock buy or sell
: Fresh data from the Heart Rhythm 2026 conference continues to support the safety and efficacy of key franchises like FARAPULSE and WATCHMAN . The Sell Case: Rising Risks Data at Heart Rhythm 2026 highlight key Boston
: Management announced a $2 billion share repurchase program for Q2, signaling confidence in the stock's long-term value. : Despite trimming price targets, the consensus remains
: Despite trimming price targets, the consensus remains a Moderate Buy .
: The company reported Q1 2026 revenue of $5.20B and adjusted EPS of $0.80, both slightly beating market expectations.